4.7 Review

Antimicrobial Peptides in Early-Life Host Defense, Perinatal Infections, and Necrotizing Enterocolitis-An Update

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 17, Pages -

Publisher

MDPI
DOI: 10.3390/jcm11175074

Keywords

antiproteases; defensins; chorioamnionitis; fetus; hepcidin; host defense peptides; lactoferrin; LL-37; neonate; sepsis

Ask authors/readers for more resources

Host defense against early-life infections relies primarily on innate immunity, in which AMPs play a major role. AMPs possess antimicrobial, immunomodulating, anti-inflammatory, and tissue-repairing properties. Studies suggest that AMPs are involved in the pathogenesis of chorioamnionitis, neonatal sepsis, and NEC, and their expression and levels may be associated with disease severity. Therefore, AMPs have potential significance in the diagnosis, prevention, prognosis, and treatment of early-life infections.
Host defense against early-life infections such as chorioamnionitis, neonatal sepsis, or necrotizing enterocolitis (NEC) relies primarily on innate immunity, in which antimicrobial peptides (AMPs) play a major role. AMPs that are important for the fetus and neonate include alpha and beta defensins, cathelicidin LL-37, antiproteases (elafin, SLPI), and hepcidin. They can be produced by the fetus or neonate, the placenta, chorioamniotic membranes, recruited neutrophils, and milk-protein ingestion or proteolysis. They possess antimicrobial, immunomodulating, inflammation-regulating, and tissue-repairing properties. AMPs are expressed as early as the 13th week and increase progressively through gestation. Limited studies are available on AMP expression and levels in the fetus and neonate. Nevertheless, existing evidence supports the role of AMPs in pathogenesis of chorioamnionitis, neonatal sepsis, and NEC, and their association with disease severity. This suggests a potential role of AMPs in diagnosis, prevention, prognosis, and treatment of sepsis and NEC. Herein, we present an overview of the antimicrobial and immunomodulating properties of human AMPs, their sources in the intrauterine environment, fetus, and neonate, and their changes during pre- and post-natal infections and NEC. We also discuss emerging data regarding the potential utility of AMPs in early-life infections, as diagnostic or predictive biomarkers and as therapeutic alternatives or adjuncts to antibiotic therapy considering the increase of antibiotic resistance in neonatal intensive care units.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available